At 6.3% CAGR, the Europe CIN & HR-HPV Treatment Market is projected to be worth US$ 5,119.63 million by 2028, says The Business Market Insights

According to the Business Market Insights’ research, the Europe CIN & HR-HPV treatment market was valued at US$ 3,771.58 million in 2023 and is expected to reach US$ 5,119.63 million by 2028, registering a CAGR of 6.3% from 2023 to 2028. Favorable initiatives for preventing cervical cancer and increase in prevalence of human papillomavirus infections are the critical factors attributed to the Europe CIN & HR-HPV treatment market expansion. 

In August 2020, the World Health Organization (WHO) devised a strategy for the elimination of cervical cancer. Per this strategy, all countries across the region must focus on reaching and maintaining an incidence rate of less than 4 per 100,000 women to eliminate cervical cancer. To attain such low incidence rates, countries should focus on cervical cancer screening, treatment, and vaccination. Medicare, a popular government insurance program, provides coverage for PAP tests, pelvic exams, and clinical breast examinations performed every two years for cervical cancer screening.

Unitaid, a global health agency that works to bring about innovative solutions to prevent, diagnose, and treat major diseases in low- and middle-income countries, has come up with a new initiative for cervical cancer prevention. Its efforts are focused on expanding access to critical tools and services to screen for the early signs of cervical cancer, followed by the treatment of positive cases. Unitaid is providing support for the Clinton Health Access Initiative (CHAI) and the Scale Up Cervical Cancer Elimination with Secondary Prevention Strategy (SUCCESS) Project, which are being carried out in partnership with Expertise France, Jhpiego, and the Union for International Cancer Control (UICC).

Such initiatives by various healthcare organizations and governments for preventing cervical cancer boost the growth of the CIN & HR-HPV treatment market.

On the contrary, increased reoccurrence rate and high cost of CIN & HR-HPV treatment hurdles the growth of Europe CIN & HR-HPV treatment market.

Based on disease type, the Europe CIN & HR-HPV treatment market is segmented into cervical intraepithelial neoplasia 1 (CIN 1), cervical intraepithelial neoplasia 2 (CIN 2), and cervical intraepithelial neoplasia 3 (CIN 3). The cervical intraepithelial neoplasia 3 (CIN 3) segment held 49.0% market share in 2023, amassing US$ 1,849.22 million. It is projected to garner US$ 2,612.53 million by 2028 to expand at 7.2% CAGR during 2023–2028.

Based on strain type, the Europe CIN & HR-HPV treatment market is segmented into HPV 16, HPV 18, and others. The HPV 16 segment held 63.1% market share in 2023, amassing US$ 2,381.14 million. It is projected to garner US$ 3,237.82 million by 2028 to expand at 6.3% CAGR during 2023–2028.

Based on offering, the Europe CIN & HR-HPV treatment market is bifurcated into diagnostic methods and treatments. The treatments segment held 72.1% market share in Europe CIN & HR-HPV treatment market in 2023, amassing US$ 2,721.11 million. It is projected to garner US$ 3,600.09 million by 2028 to expand at 5.8% CAGR during 2023–2028. Further, diagnostic methods are segmented into pap smear, HPV testing, colposcopy, and biopsy. Further, treatments are bifurcated into excision surgery and ablation techniques.

Based on product type, the Europe CIN & HR-HPV treatment market is segmented into kits & reagents, instruments, and services. The services segment held 60.0% market share in 2023, amassing US$ 2,264.19 million. It is projected to garner US$ 3,088.89 million by 2028 to expand at 6.4% CAGR during 2023–2028.

Based on end user, the Europe CIN & HR-HPV treatment market is segmented into hospitals & clinics, diagnostic laboratories, specialized clinical laboratories, and others. The hospitals & clinics segment held 49.6% market share in 2023, amassing US$ 1,872.22 million. It is projected to garner US$ 2,507.98 million by 2028 to expand at 6.0% CAGR during 2023–2028.

Based on country, the Europe CIN & HR-HPV treatment market has been categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe.  Our regional analysis states that Germany captured 25.4% market share in Europe CIN & HR-HPV treatment market in 2023. It was assessed at US$ 958.86 million in 2023 and is likely to hit US$ 1,336.58 million by 2028, exhibiting a CAGR of 8.9% during the forecast period.  

Key players dominating the Europe CIN & HR-HPV treatment market are Fujirebio Europe NV; Qiagen NV; Zilico Ltd; Abbott Laboratories; F. Hoffmann-LA Roche Ltd; Bioneer Corp; and Thermo Fisher Scientific Inc among others.   

• In June 2022, Roche launches a HPV self-sampling solution.
• In Feb 2021, QIAGEN and INOVIO expand collaboration.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com